Incidence of Endophthalmitis After Prophylactic Intracameral Injection of Moxifloxacin

Monday, April 20, 2015: 4:16 PM
Room 1B (San Diego Convention Center)
Celso Boianovsky, MD
Jonathan C. Lake, MD
Thais J. Saraiva, MD

To report the incidence of endophthalmitis after adoption of prophylactic intracameral injection of moxifloxacin at the Brasília Hospital of Vision in Brazil.

Retrospective review of the charts of 7195 eyes (5576 patients) that underwent uneventful phacoemulsification with IOL implantation from January, 2009, to December, 2013. The patients were divided in two groups: Group A (n=3515), that followed standard prophylaxis of endophthalmitis; Group B (n=3680), that followed the same protocol and intracameral injection of 0.05cc moxifloxacin as the final step of the surgery. Statistical analysis was performed with Fisher’s Exact Test to compare endophthalmitis rates of both groups.

Mean age of the patients was 67.8+_8.96 (48 to 83 years). 53.8% were female and 46.2% were male. Endophthalmitis rate in Group A was 0.22% (8 in 3515 cases). Endophthalmitis rate in Group B was 0.03% (1 in 3680). Fisher’s Exact Test showed a significantly lower rate in Group B (p=0.0198).

Prophylactic intracameral injection of moxifloxacin lowered the rate of endophalmitis in this study.